Search

Displaying results 5591 - 5600 of 8974 in total
  1. Drug

    VPM4001

    go.drugbank.com/drugs/DB05089
    Experimental

    VPM4001 is an allogeneic vaccine for treatment of prostate carcinoma. … It consists of irradiated human LNCaP cells that have been genetically modified to permanently secrete interferon-γ and interleukin-2 (LNCaP/IL-2/IFN-γ).

  2. Drug

    Rocatinlimab

    go.drugbank.com/drugs/DB18809
    Investigational

    Rocatinlimab is a subcutaneously administered anti-OX40 antibody developed for the treatment of moderate-to-severe atopic dermatitis. … In clinical trials, it has shown significant efficacy and safety compared to a placebo.

  3. Drug

    Cixutumumab

    go.drugbank.com/drugs/DB12250
    Investigational

    Cixutumumab is a highly specific recombinant human monoclonal antibody with high affinity for the insulin-like growth factor-I receptor (IGF-IR). IGF-IR is overexpressed in a variety of tumour types.

  4. Drug

    Torcetrapib

    go.drugbank.com/drugs/DB06281
    Investigational

    Torcetrapib (CP-529414, Pfizer) was developed to treat hypercholesterolemia but its development was halted in 2006 when phase III studies showed excessive mortality in the treatment group receiving a combination

  5. Drug

    Iron protein succinylate

    go.drugbank.com/drugs/DB11209
    Approved

    Mixtures: KOMFER FOL 40 MG/185 MCG ORAL COZELTI, 10 FLK., KOMFER FOL 40 MG/185 MCG ORAL COZELTI, 20 FLK.
  6. Drug

    Seliciclib

    go.drugbank.com/drugs/DB06195
    Investigational

    Developed by Cyclacel, seliciclib is being researched for the treatment of non-small cell lung cancer (NSCLC), leukemia, HIV infection, herpes simplex infection, and the mechanisms of chronic inflammation … R-roscovitine (Seliciclib or CYC202) is a cyclin-dependent kinase (CDK) inhibitor that preferentially inhibits multiple enzyme targets including CDK2, CDK7 and CDK9, which alter the growth phase of treated

  7. Drug

    Alipogene tiparvovec

    go.drugbank.com/drugs/DB13521
    Approved

    It is being investigated for the treatment of lipoprotein lipase (LPL) deficiency.[A259796, A259801, A259806, A259811]

  8. Drug

    Vitex agnus-castus fruit extract

    go.drugbank.com/drugs/DB13193
    Investigational

    The main mechanism of action of vitex agnus-castus fruit extract has not been fully elucidated, however it is suggested to modulate the stress-induced prolactin secretion via dopaminergic actions, and

    Mixtures: Menopause Relief for Women
  9. Drug

    S-40503

    go.drugbank.com/drugs/DB13938
    Experimental

    S-40503 is an investigational selective androgen receptor modulator (SARM) developed for the treatment of osteoporosis by the Japanese company Kaken Pharmaceuticals.

  10. Drug

    AAV-dXIAP

    go.drugbank.com/drugs/DB17880
    Experimental

    AAV-dXIAP is a recombinant adeno-associated virus-encoded gene for X-linked mammalian inhibitor of apoptosis protein (XIAP) developed by Neurologix.